Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

A post hoc analysis of the SRMOUNT-1 study finds weight loss from the use of tirzepatide was associated with strong benefits ...

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

All doses of once-weekly tirzepatide better than insulin degludec for HbA1c reduction. ... Horowitz M "Twincretin therapy for type 2 diabetes: how do two do?" Lancet 2021; DOI: 10.1016/S0140-6736 ...

Eli Lilly's tirzepatide weight-loss drug just got FDA approval. It is cheaper and possibly more effective than Ozempic or Wegovy, ... (GIP), which is why it's sometimes called a "twincretin" drug.

Diabetes drug Tirzepatide, which is shown to be more effective than Wegovy and Ozempic, is likely to be approved by the Food and Drug Administration for weight loss in 2023 and is expected to be ...

Tirzepatide is approved as Mounjaro in T2D but not yet in weight loss, although that looks a formality. The drug is seemingly of generational importance and as high as Lilly's stock has risen ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

About 82% of participants taking tirzepatide experienced 5% or greater weight loss. In comparison, only 66.5% of participants taking semaglutide achieved this level of weight loss. Which one to choose ...

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

Tirzepatide (TZP; LY3298176) is a novel pharmacological innovation developed by Eli Lilly and Company in 2016 that combines both GLP-1 and GIP into a single subcutaneous weekly injection.